SAN FRANCISCO, CA, Sep 23, 2010 (MARKETWIRE via COMTEX News Network) --
Medizone International, Inc. (OTCBB: MZEI) (OTCQB: MZEI) announced today the Company has filed a fourth U.S. Provisional patent application involving what it terms, "Advanced Oxidative Sterilization Processes."
Dr. Michael Shannon, Director of Medical Affairs, explained, "We are now exploring a new development in the field of oxidative chemistry which we believe will have a significant impact on our future technology and the ease with which we can effectively decontaminate hospitals, chronic care facilities, veterinary facilities, hotels, cruise ships, sports facilities and the equipment therein. Our research to date clearly demonstrates that the combination of modest levels of ozone and low concentrations of peroxide, properly delivered at the right temperature and humidity, will reliably eliminate bacterial loads of at least 6 logs (sterilization standard) on a broad range of surface materials, including carpets, for all of the 'Superbugs' responsible for Hospital Acquired Infections. This new development, however, further enhances Medizone's AsepticSure(TM) technology in a manner not anticipated. In fact, decontamination in the future will very likely be based on unique combinations of what we are calling 'Advanced Oxidative Sterilization Processes' which build on the existing technology by using a family of chemical moieties considered to be even more potent than either ozone or peroxide to destroy a broad range of potentially lethal pathogens. Research is now underway at our laboratories in Kingston on a parallel track with our hospital beta testing program to evaluate the merits of a multifactorial decontamination system which appears to further increase the potency of AsepticSure(TM) while dramatically reducing the exposure time, both of which have major implications for certain applications."
Medizone's CEO, Edwin Marshall, added, "With two international patent applications filed in addition to the four U.S. provisional applications now in place, we are taking the steps we believe necessary to fully protect the commercial rights of Medizone International. It is now clear that what began as a technology to decontaminate and sterilize hospital spaces has grown into the foundations of an entirely new sterilization industry. We are developing a family of solutions based on the nuances of specific applications. Given the outcomes of recent meetings with both private industry players and government, it is clear we are not alone in recognizing this concept. As I announced in a recent interview with Don Baillargeon for a segment of his show, 'MoneyTV,' to be aired this coming Saturday, we have even filed a patent application addressing the bed bug issue for the cruise ship and hotel industry. We are not making too much of it yet, as the science for that application remains to be completed. However, we are guardedly optimistic that we will be able to provide an effective and affordable solution to that market segment as well, and thus wanted to get the IP protection in place as soon as possible."
Medizone International, Inc. is a research and development company engaged in developing its AsepticSure(TM) System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures with additional variants for sports facilities and food processing applications and, potentially, the hotel and cruise ship industry for bed bug eradication and Norwalk virus.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact: Investor Relations The Eversull Group, Inc. Jack Eversull Email Contact 972-571-1624 fax: 214-469-2361 web site: www.medizoneint.com E-mail: Email Contact
SOURCE: Medizone International, Inc.
https://www2.marketwire.com/mw/emailprcntct?id=8FB20C2F6FB9EDE4 https://www.medizoneint.com https://www2.marketwire.com/mw/emailprcntct?id=14FF811953423450
Copyright 2010 Marketwire, Inc., All rights reserved.